SUOMEN AKATEMIA Terveyden tutkimuksen toimikunta

Transkriptio

1 SUOMEN AKATEMIA Terveyden tutkimuksen toimikunta TERVEYDEN TUTKIMUKSEN TOIMIKUNNALTA KLIINISEN TUTKIJAURAN TUKEMISTA HAKENEILLE ( päättynyt haku) Arvoisa hakija, Suomen Akatemian terveyden tutkimuksen toimikunta päätti kokouksessaan rahoitettavista kliinisen tutkijanuran tutkimusmäärärahoista. Hakija saa rahoituspäätöksestä automaattisen ilmoituksen sähköpostiinsa. Rahoitetut hankkeet ovat nähtävissä Akatemian verkkosivuilla osoitteessa kohdassa Päätökset ja vaikutukset > Rahoituspäätökset. Terveyden tutkimuksen toimikunnalle osoitettiin mennessä 34 kliinisen tutkijanuran tutkimusmääräraha hakemusta. Toimikunta päätti kokouksessaan rahoittaa 10 hanketta yhteensä noin 1,77 miljoonalla eurolla, joka vastaa 29 % hakemuksista. Toimikunta päätti kokouksessaan asettaa viisi hakemusta varasijalistalle. Mikäli joku kliinisen tutkimuksen tutkimusmäärärahan saajista kieltäytyy ottamasta vastaan määrärahaa, listalle kuuluville hankkeille tarjotaan rahoitusta varasijalistan osoittamassa järjestyksessä. Rahoituksen maksaminen edellyttää vastuullisen johtajan sekä suorituspaikan vahvistusta rahoituksen vastaanottamisesta Akatemian verkkoasioinnin ( kautta kuuden viikon kuluessa päätöspäivästä ( mennessä). Kun rahoituksen vastaanotto on vahvistettu verkkoasioinnin kautta, vastuullinen johtaja ja tutkimuksen suorituspaikka hyväksyvät rahoituspäätöksen sisällön kokonaisuudessaan ja sitoutuvat noudattamaan Akatemian asettamia rahoituksen käyttöön liittyviä ehtoja. Rahoituspäätöksiin liittyvät ehdot on esitetty sivuilla Tarvittaessa, vastuullinen johtaja voi tehdä ehdotuksen kustannusarvion muutoksesta kuuden viikon kuluessa päätöspäivästä Akatemian verkkoasioinnissa. Ohjeet löytyvät Akatemian verkkosivuilta Hakemukset arvioitiin kansainvälisissä arviointipaneeleissa (liite 1), jotka kokoontuivat tammihelmikuussa Helsingissä. Paneelit ovat arviointityössään käyttäneet tarvittaessa lisäasiantuntemusta toisen paneelin jäseniltä tai ulkopuolisilta asiantuntijoilta. Paneeli keskusteli jokaisesta hakemuksesta ja antoi niistä arvosanan sekä kirjallisen lausunnon, joka on luettavissa verkkoasioinnissa hakijan omilla tunnuksilla. Kaikki paneelin jäsenet vastaavat yhteisesti annetusta lausunnosta. Arviointipaneelit pitivät hakemusten tieteellistä laatua yleisesti erittäin hyvänä, parhaita arvosanoja saaneita hankkeita pidettiin kilpailukykyisinä kansainvälisellä tasolla. Tutkimussuunnitelmien tieteellisestä laadusta tehtiin yhteenveto (liite 2), jossa asiantuntijapaneelit nostivat esille yleisimpiä ja usein toistuvia tutkimussuunnitelman laatuun vaikuttavia seikkoja.

2 Kliinisen tutkijanuran hakemusten arvosanojen jakauma, päättynyt haku (34 hakemusta) 12 Arvosanajakauma Hakijat sinisellä, myönnöt punaisella Terveyden tutkimuksen toimikunta perehtyi hakemuksiin kiinnittäen erityistä huomiota paneelin antamiin lausuntoihin. Rahoituspäätöksiä tehdessään toimikunta piti tieteellistä laatua ensisijaisena ja tärkeimpänä asiana päätöksenteossa. Mikäli sinulla on hakuun liittyviä kysymyksiä tai kommentteja, pyydän ottamaan yhteyttä sähköpostitse tai puhelimitse. Sanna Marjavaara Tiedeasiantuntija Puh sanna.marjavaara@aka.fi

3 Liite 1 Grant review panel experts Research Council of Health September 2013 call (Academy Projects, Academy Research Fellows, Postdoctoral Researchers, Clinical Researchers, Finnish-Japanese joint call on medical genomics, MEC funded call on sport science) Panel 1 1. Professor Lightowlers, Robert; Newcastle University, UK 2. Professor Brand, Thomas; Imperial College London, UK 3. Professor Cuppen, Edwin; Hubrecht Institute and University Medical Center Utrecht, the Netherlands 4. Professor Gauguier, Dominique; INSERM, France 5. Professor van der Maarel, Silvere; Leiden University Medical Center, the Netherlands 6. Dr. Saada, Ann; Hadassah-Hebrew University Medical Center, Israel 7. Professor Speicher, Michael; Medical University of Graz, Austria 8. Professor Veltman, Joris; Radboud University Medical Center, the Netherlands 9. Professor Worthington, Jane; University of Manchester, UK External reviewer: 1. Professor de Knijff, Peter; Leiden University Medical Center, the Netherlands Panel 2 1. van Leeuwen, Hans; Erasmus, The Netherlands 2. Professor Arsenijevic, Yvan; University of Lausanne and Fondation Asile des Aveugles, Swizerland 3. Professor Bulleid, Neil; University of Glasgow, UK 4. Professor Helms, Bernd; Utrecht University, The Netherlands 5. Professor Kadler, Karl; University of Manchester, UK 6. Professor Petrie, John; University of Glasgow, UK 7. Professor Schenke-Layland, Katja; University Tübingen, Germany 8. Professor Stojkovic, Miodrag; University of Kragujevac, Serbia External reviewer: 1. Professor Haanen, John; Netherlands Cancer Institute, The Netherlands 2. Professor Duchen, Michael; University College London, UK Panel 3 1. Professor Isacke, Clare; Breakthrough Breast Cancer Research Centre, UK 2. Service of Oncology Director GU Carles, Joan; University Hospital Vall Hebron, Spain 3. Professor Gissmann, Lutz; Deutsches Krebsforschungszentrum (DKFZ), Germany 4. Head of Medical Oncology Haanen, John; Netherlands Cancer Institute, The Netherlands 5. Associate Professor Hansen, Lise Lotte; Aarhus universitet, Denmark 6. Associate Professor Marosi, Christine; Medical University of Vienna, Austria 7. Dr. Marra, Giancarlo University of Zurich, Swizerland

4 8. Professor O'Driscoll, Lorraine; Trinity College Dublin, Ireland 9. Professor Ryan, Anderson; University of Oxford, UK 10. Associate Professor Wiemer, Erik; Erasmus University Medical Center, The Netherlands Panel 4 1. Professor Krombach, Fritz; Ludwig-Maximilians-Universität München, Germany 2. Professor Agerberth, Birgitta; Karolinska Institutet, Sweden 3. Dr. Cerf-Bensussan, Nadine; Instituti National de la Santé et de la Recherche, France 4. Researcher Durandy, Anne; INSERM, France 5. Professor Geretti, Anna Maria; University of Liverpool, UK 6. Professor Goodbourn, Steve; St. George's, University of London, UK 7. Professor Hawrylowicz, Catherine; King's College London, UK 8. Dr. Lehuen, Agnes; INSERM U1016; France 9. Professor Maiden, Martin; University of Oxford, UK 10. Professor Simmonds, Peter; University of Edinburgh, UK External reviewers: 1. Professor Cuppen, Edwin; Hubrecht Institute and University Medical Center Utrecht, The Netherlands 2. Profesor Hughes, Francis; King s College London, UK 3. Professor Reichhart, Jean-Marc; University de Strasbourg, France 4. Professor Walters, Matthew; University of Glasgow, UK 5. Professor Worthington, Jane; University of Manchester, UK Panel 5 1. Professor Shaw, Pamela J; University of Sheffield, UK 2. Professor Amor, Sandra; VU University Medical Center, The Netherlands 3. MD; Dodel, Richard; Philipps-University Marburg, Germany 4. Professor Gilhus, Nils Erik; University of Bergen, Norway 5. Associate Professor Kozicz, Tamas; Radboud University Nijmegen, The Netherlands 6. Professor Lundervold, Arvid; University of Bergen, Norway 7. Professor Matthews, Paul; Imperial College London, UK 8. Professor Pasinetti, Giulio; Icahn School of Medicine at Mount Sinai, USA 9. Professor Sirén, Anna-Leena; University of Würzburg, Germany 10. Professor Spillantini, Maria Grazia; University of Cambridge, UK Panel 6 1. Professor Frøkjær, Sven; University of Copenhagen, Denmark 2. Professor Caliceti, Paolo; University of Padova, Italy 3. Professor Danielson, Helena; Uppsala Universitet, Sweden 4. Professor Haycock, John W; University of Sheffield, UK 5. Director Hartmann, Rolf W.; Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Germany 6. Professor Klein, Jochen; Goethe University, Germany

5 7. Professor Schmidt, Martina; University of Groningen, The Netherlands 8. Dean De Smedt, Stefaan; Ghent University Belgium, Belgium 9. Professor Sylte, Ingebrigt; University of Tromsø, Norway 10. Associate Professor Vistoli, Giulo; University of Milan, Italy Panel 7 1. Professor Kinman, Gail; University of Bedfordshire, UK 2. Reader Dr Batty, David; University College London, UK 3. Professor Buntinx, Frank; KU Leuven, Belgium 4. Senior Lecturer Dr Evans, Jonathan; University of Bristol, UK 5. Professor Friis, Svein; Oslo University Hospital, Norway 6. Professor Hultman, Christina; Karolinska Institutet, Sweden 7. Professor Van Oyen, Herman; Scientific Institute of Public Health, Belgium 8. Professor Rokne, Berit; University of Bergen, Norway 9. Professor Sacker, Amanda; University College London, UK 10. Professor Wagner, Cordula; Netherlands institute for health services research NIVEL, The Netherlands External reviewer: 1. Professor Franks, Paul W.; Lund University, Sweden Panel 8 1. Professor Wabitsch, Martin; Division of Pediatric Endocrinology and Diabetes, Adipocyte Research Laboratory, University of Ulm, Germany 2. Professor Ahlbom, Anders; Karolinska Institutet, Sweden 3. Professor Avenell, Alison; University of Aberdeen, UK 4. Professor Blaut, Michael; German Institute of Human Nutrition, Germany 5. Professor Feskens, Edith; Wageningen University; The Netherlands 6. Professor Franks, Paul W.; Lund University, Sweden 7. Professor Kafatos, Anthony; University of Crete, Greece 8. Professor Hoffmann, Barbara; Heinrich Heine University of Düsseldorf, Germany 9. Dr. Raaschou-Nielsen, Ole; Danish Cancer Society Research Center, Denmark 10. Professor Roche, Helen; Conway Institute of Biomolecular & Biomedical Research, Ireland Panel 9 1. Professor Norman, Jane; University of Edinburgh, UK 2. Professor Aspenberg, Per; Linköpings universitet, Sweden 3. Professor Atar, Dan; Oslo University Hospital and University of Oslo, Institute of Clinical Medicine, Norway 4. Professor Casas, Juan P; London School of Hygiene and Tropical Medicine, UK 5. Professor Diez-Perez, Adolfo; Salut Mar. Autonomous University of Barcelona, Spain 6. Professor Hindmarsh, Peter; University College London, UK 7. Professor Hiort, Olaf; University of Lübeck, Germany 8. Professor Pasterkamp, Gerard; Utrecht University, The Netherlands

6 9. Professor Walters, Matthew; University of Glasgow, UK External reviewers: 1. Professor Burkhard, Fiona; Bern University Hospital, Germany 2. Dr. Cerf-Bensussan, Nadine; Instituti National de la Santé et de la Recherche, France 3. Senior Lecturer Grupen, Christopher; University of Sydney, Australia 4. Professor Hughes, Francis; King s College London, UK 5. Senior Researcher van der Ploeg, Hidde; VU University Medical Centre, Dept. of Public & Occupational Health, The Netherlands 6. Professor Proctor, Gordon; King's College London Dental Institute, UK 7. Professor Hughes, Francis; King s College London, UK 8. Professor O Brien, Colm; Mater Hospital, Ireland 9. Associate Professor Shaal, Shlomit; University of Louisville School of Medicine, USA Panel Professor Mittnacht, Sibylle; UCL Cancer Institute cancer, UK 2. Professor Dantuma, Nico; Karolinska Institutet, Sweden 3. Professor Sandrine, Etienne-Manneville; Institut Pasteur CNRS, France 4. Dr. Gavard, Julie; Institut Cochin CNRS, France 5. Professor Gruenbaum, Yosef; The Hebrew University of Jerusalem, Israel 6. Professor Müller, Anne; University of Zurich, Swizerland 7. Professor Olson, Michael; Beatson Institute for Cancer Research, UK 8. Dr. Wagner, Erwin F.; Centro Nacional de Investigaciones Oncológicas (CNIO), Spain Panel Professor van Baak, Marleen; Maastricht University, The Netherlands 2. Dr Gill, Jason; University of Glasgow, UK 3. Professor Fairclough, Stuart; Liverpool John Moores University, UK 4. Professor emeritus Hopman-Rock, Marijke; Body@Work research center TNO and VU university medical center, The Netherlands 5. Professor Newham, Di; King's College London, UK 6. Associate Professor Overgaard, Kristian; Aarhus University, Denmark 7. Senior Researcher van der Ploeg, Hidde; VU University Medical Centre, Dept. of Public & Occupational Health, The Netherlands External reviewer: 1. Professor Schelbert, Heinrich; Ronald Reagan UCLA Medical Center, USA 2. Associate Professor Sebe, Niculae; University of Trento, Italy 3. Professor Skelton, Dawn; Glasgow Caledonian University, UK Panel Professor Armour, Kathleen; University of Birmingham, UK 2. Professor Cardon, Greet; Ghent University, Belgium 3. Professor Ellaway, Anne; Medical Research Council University of Glasgow, UK 4. Professor Memmert, Daniel; German Sport University, Germany

7 5. Associate Professor Ottesen, Laila; University of Copenhagen, Denmark 6. Professor Scheerder, Jeroen; University of Leuven, Belgium External reviewers: 1. Professor Newham, Di; King's College London, UK 2. Professor Shaw, Pamela J; University of Sheffield, UK

8 Liite 2 September 2013 call applications submitted to Research Council for Health Feedback from the grant review panel members to the applicants Scientific quality of the applications in general was similar to that of other countries. The very best were clearly of high quality and internationally competitive. However, there was a broad range in the quality of the applications. The panels observed some common weaknesses, addressing which would significantly improve most applications: Often, the research plans were not well structured and they needed improvement. Many plans lacked cohesion to a greater or lesser extent. The different parts of the plan have to interact with each other and with one or more overall objectives. Too often there were not enough details to judge the feasibility of the proposed projects. Preliminary data should be included into the plan to in order for the panel to assess the feasibility of a research plan. Although it is important to give a suitable background, many research plans had too long background sections. The reviewers are particularly interested in the justifications and methodology of the current proposal (also data analyses). There was frequently a lack of linkage between the research questions and the research methods. There were several applications where the ideas appeared to be novel and of a very high standard, but the plans were poorly structured, unfocused and not always clear aims or hypotheses. The statistical and data analyses plans were often inadequate. A common issue is the lack of suitable power calculations. In many research plans they were simply absent, and in others they were not adequate. Even one critical omission such as this will reduce the opportunity for funding. A big problem is the over-ambition of several projects, an unrealistic view of what can be done during the funding period. Often, less is more with a research plan! Furthermore, the plans were too often more like a collection of studies or a large research programme than having a clearly defined and focused goal with well-planned time schedule for the funding period. More emphasis is needed on what will be done in this particular proposal during the funding period and by whom, instead of what has been already done. It is also important to clearly indicate the data that have already been obtained and differentiate this from what is in process, and what will be done in the future. This will avoid confusion. International collaborations and mobility plan were often mentioned without coherent arguments why these have been chosen or planned. The panel members encourage researchers to publish in higher ranking journals. To summarize, the applicants can become more competitive by international standards by writing a focused research plan with clearly defined goal and hypotheses, providing rationale and details for the methods, describing in detail the power calculations and data analyses and also by giving justification for collaborations.